Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

The new approval is a boost for Sanofi because the VRd regimen has become the preferred first-line treatment option for transplant-ineligible multiple myeloma patients in recent years, giving ...

Sanofi continues to advance Sarclisa as part ... malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. | Johnson & Johnson is ...

Groundbreaking research at the Yale Cancer Center offered hope for patients diagnosed with Multiple Myeloma, a type of blood ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promis ...

In striving to become the number one immunoscience company globally, Sanofi remains committed ... with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types ...

Sanofi continues to advance Sarclisa as part ... malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well ...